Convalescent Plasma for Coronavirus

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Coronavirus+4 MoreConvalescent Plasma - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether an experimental treatment, convalescent plasma, can help people with COVID-19. The treatment will be given to people who are hospitalized and researchers will monitor how well it works.

Eligible Conditions
  • Coronavirus

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 14 days

14 days
Correlation between the NAb dose titer in the convalescent plasma and change or lack of change when comparing pre-treatment and day one NAb titers to inpatients with documented COIVD-19 infection
Number of participants with clearance of viral shedding of SARSCoV-2 in nasopharyngeal or nasal samples
Rapid deterioration as evidenced by increase in ordinal or news score within 4 hours of transfusion

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Side Effects for

Convalescent Plasma
12%Pneumonia
4%Infusion related reaction
2%Hypoxia
2%Dyspnea
1%Acute respiratory failure
1%Migraine
1%Fatigue
1%Dehydration
1%Vomiting
1%Flank pain
1%Pulmonary embolism
1%Dizziness
1%Chest pain
This histogram enumerates side effects from a completed 2021 Phase 3 trial (NCT04355767) in the Convalescent Plasma ARM group. Side effects include: Pneumonia with 12%, Infusion related reaction with 4%, Hypoxia with 2%, Dyspnea with 2%, Acute respiratory failure with 1%.

Trial Design

1 Treatment Group

Single Arm
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Convalescent Plasma · No Placebo Group · Phase 2

Single Arm
Drug
Experimental Group · 1 Intervention: Convalescent Plasma · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
COVID-19 convalescent plasma
Not yet FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 14 days

Who is running the clinical trial?

University of New MexicoLead Sponsor
340 Previous Clinical Trials
3,537,344 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Patient (or LAR) is willing and able to provide written informed consent and comply with all protocol requirements.
You are eligible for the study if you are at least 18 years of age.
For patients unable to consent, consent by the legally authorized representative (LAR) may be obtained by phone.
You are hospitalized with COVID-19 respiratory symptoms and confirmation via COVID-19 SARS-CoV-2 RT-PCR testing.
References